IL41416A - Injectable oily peptide preparations and their manufactur - Google Patents
Injectable oily peptide preparations and their manufacturInfo
- Publication number
- IL41416A IL41416A IL41416A IL4141673A IL41416A IL 41416 A IL41416 A IL 41416A IL 41416 A IL41416 A IL 41416A IL 4141673 A IL4141673 A IL 4141673A IL 41416 A IL41416 A IL 41416A
- Authority
- IL
- Israel
- Prior art keywords
- preparations
- peptide
- contain
- process according
- usable salts
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 35
- 150000003839 salts Chemical class 0.000 claims 25
- 238000000034 method Methods 0.000 claims 22
- 235000001014 amino acid Nutrition 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims 16
- 229930195729 fatty acid Natural products 0.000 claims 16
- 239000000194 fatty acid Substances 0.000 claims 16
- -1 fatty acid salts Chemical class 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 159000000013 aluminium salts Chemical class 0.000 claims 7
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- 239000003921 oil Substances 0.000 claims 7
- 235000019198 oils Nutrition 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 150000004671 saturated fatty acids Chemical class 0.000 claims 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 7
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 6
- 239000002156 adsorbate Substances 0.000 claims 5
- 235000003441 saturated fatty acids Nutrition 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 3
- 239000000813 peptide hormone Substances 0.000 claims 3
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 2
- 235000019483 Peanut oil Nutrition 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000004411 aluminium Substances 0.000 claims 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000312 peanut oil Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH229972A CH574247A5 (en) | 1972-02-17 | 1972-02-17 | Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity |
| CH1782972 | 1972-12-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL41416A0 IL41416A0 (en) | 1973-03-30 |
| IL41416A true IL41416A (en) | 1976-03-31 |
Family
ID=25690055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL41416A IL41416A (en) | 1972-02-17 | 1973-01-29 | Injectable oily peptide preparations and their manufactur |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US3869549A (pm) |
| JP (1) | JPS4892516A (pm) |
| AR (1) | AR197116A1 (pm) |
| AT (1) | AT335615B (pm) |
| AU (1) | AU472655B2 (pm) |
| BE (1) | BE795516A (pm) |
| CS (1) | CS172967B2 (pm) |
| DD (1) | DD102584A5 (pm) |
| DE (1) | DE2306075A1 (pm) |
| DK (1) | DK134098B (pm) |
| ES (1) | ES411655A1 (pm) |
| FR (1) | FR2181734B1 (pm) |
| GB (1) | GB1418408A (pm) |
| IE (1) | IE37151B1 (pm) |
| IL (1) | IL41416A (pm) |
| NL (1) | NL7300953A (pm) |
| PL (1) | PL90318B1 (pm) |
| SE (1) | SE7600435L (pm) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2254061A1 (de) * | 1972-11-04 | 1974-05-16 | Hoechst Ag | Lh-releasing hormon zur nasalen applikation |
| DE2254043C2 (de) * | 1972-11-04 | 1985-01-24 | Hoechst Ag, 6230 Frankfurt | LH-Releasing Hormon zur nasalen Applikation |
| JPS528375B2 (pm) * | 1973-07-02 | 1977-03-09 | ||
| GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| JPS55118415A (en) * | 1979-02-28 | 1980-09-11 | Pii Papahadojiyopo Dometoriosu | Method of encapsulating biologically active substance in lipoid cell |
| US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5474980A (en) * | 1984-10-04 | 1995-12-12 | Monsanto Company | Prolonged release of biologically active somatotropins |
| US5086041A (en) * | 1984-10-04 | 1992-02-04 | Monsanto Company | Methods of using prolonged release somatotropin compositions |
| KR890002631B1 (ko) * | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
| DE3502099A1 (de) * | 1985-01-23 | 1986-08-07 | Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold | Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel |
| US4804742A (en) * | 1985-06-06 | 1989-02-14 | Rorer Pharmaceutical Corporation | Amide analogs of calcitonin |
| US4650854A (en) * | 1985-06-06 | 1987-03-17 | Usv Pharmaceutical Corporation | Amide analogs of calcitonin |
| US4775659A (en) * | 1985-08-19 | 1988-10-04 | Eli Lilly And Company | Injectable semi-solid formulations |
| IL79765A (en) * | 1985-08-23 | 1992-02-16 | Lilly Co Eli | Injectable sustained release formulations of bovine somatotropin |
| US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5179079A (en) * | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| KR19990071255A (ko) | 1998-02-28 | 1999-09-15 | 성재갑 | 소마토트로핀과 비타민의 합제 조성물 |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| CA2563533C (en) * | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| EP3421031A1 (en) | 2006-08-09 | 2019-01-02 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| MX2009011123A (es) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
| JP5658031B2 (ja) | 2007-06-22 | 2015-01-21 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成 |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| MX2011002836A (es) | 2008-09-17 | 2011-04-28 | Chiasma Inc | Composiciones farmaceúticas y métodos de administración relacionados. |
| WO2010056657A2 (en) | 2008-11-16 | 2010-05-20 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
| NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9956164B2 (en) | 2014-04-16 | 2018-05-01 | Veyx-Pharma Gmbh | Veterinary pharmaceutical composition and use thereof |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| EP3253401B1 (en) | 2015-02-03 | 2025-04-02 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
| AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| CL2016000217A1 (es) * | 2016-01-27 | 2016-07-01 | Farmacologia En Aquacultura Veterinaria Fav S A | Nueva composición veterinaria inyectable para la sincronización del desove en peces |
| JP7077237B2 (ja) | 2016-05-16 | 2022-05-30 | インターシア セラピューティクス，インコーポレイティド | グルカゴン受容体選択的ポリペプチド及びその使用方法 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| MX2019008006A (es) | 2017-01-03 | 2019-08-29 | Intarcia Therapeutics Inc | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE950676C (de) * | 1948-01-06 | 1956-10-11 | Bristol Lab Inc | Verfahren zur Herstellung eines injizierbaren Arzneimittels |
| DE920148C (de) * | 1951-03-31 | 1954-11-15 | Nyegaard & Co As | Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer |
| US2944940A (en) * | 1956-01-16 | 1960-07-12 | Armour & Co | Adrenocorticotrophin and zinc composition |
| US2945783A (en) * | 1957-06-20 | 1960-07-19 | Reheis Company Inc | Aluminum protein antacid and process of making |
-
0
- BE BE795516D patent/BE795516A/xx unknown
-
1973
- 1973-01-23 NL NL7300953A patent/NL7300953A/xx unknown
- 1973-01-29 IL IL41416A patent/IL41416A/en unknown
- 1973-01-29 IE IE135/73A patent/IE37151B1/xx unknown
- 1973-02-05 US US329519A patent/US3869549A/en not_active Expired - Lifetime
- 1973-02-08 DE DE2306075A patent/DE2306075A1/de active Pending
- 1973-02-14 AR AR246593A patent/AR197116A1/es active
- 1973-02-15 ES ES411655A patent/ES411655A1/es not_active Expired
- 1973-02-15 FR FR7305303A patent/FR2181734B1/fr not_active Expired
- 1973-02-15 CS CS1106A patent/CS172967B2/cs unknown
- 1973-02-15 PL PL1973160769A patent/PL90318B1/pl unknown
- 1973-02-15 AU AU52189/73A patent/AU472655B2/en not_active Expired
- 1973-02-16 AT AT140873A patent/AT335615B/de not_active IP Right Cessation
- 1973-02-16 GB GB773573A patent/GB1418408A/en not_active Expired
- 1973-02-16 DK DK86073AA patent/DK134098B/da unknown
- 1973-02-16 DD DD168904A patent/DD102584A5/xx unknown
- 1973-02-17 JP JP48018908A patent/JPS4892516A/ja active Pending
-
1976
- 1976-01-16 SE SE7600435A patent/SE7600435L/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL90318B1 (pm) | 1977-01-31 |
| DE2306075A1 (de) | 1973-08-23 |
| AR197116A1 (es) | 1974-03-15 |
| FR2181734A1 (pm) | 1973-12-07 |
| AU472655B2 (en) | 1976-06-03 |
| DD102584A5 (pm) | 1973-12-20 |
| DK134098C (pm) | 1977-02-21 |
| IL41416A0 (en) | 1973-03-30 |
| AT335615B (de) | 1977-03-25 |
| BE795516A (fr) | 1973-08-16 |
| DK134098B (da) | 1976-09-13 |
| AU5218973A (en) | 1974-08-15 |
| US3869549A (en) | 1975-03-04 |
| NL7300953A (pm) | 1973-08-21 |
| SE7600435L (sv) | 1976-01-16 |
| ES411655A1 (es) | 1976-09-01 |
| CS172967B2 (pm) | 1977-01-28 |
| IE37151L (en) | 1973-08-17 |
| ATA140873A (de) | 1976-07-15 |
| IE37151B1 (en) | 1977-05-11 |
| JPS4892516A (pm) | 1973-11-30 |
| GB1418408A (en) | 1975-12-17 |
| FR2181734B1 (pm) | 1975-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL41416A (en) | Injectable oily peptide preparations and their manufactur | |
| EP0132769B1 (de) | Pharmazeutisches Mittel zur Behandlung des Diabetes mellitus | |
| RU2194054C2 (ru) | Синтетические аналоги il-10 | |
| AR017120A1 (es) | Composiciones farmaceuticas que contienen proteina plasmatica. | |
| DE69329367D1 (de) | Wachstumshormon-enthaltendeproteinformulierung | |
| JP2016028082A (ja) | ジペプチド結合薬用剤 | |
| BR9714434A (pt) | Formulações de interferon liquidas estáveis | |
| DE68928810D1 (de) | Analoge vom menschlichen Insulin | |
| Hiltz et al. | Anti-inflammatory activity of α-MSH (11–13) analogs: Influences of alteration in stereochemistry | |
| ATE73459T1 (de) | Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten. | |
| WO2010030180A2 (en) | Peptide formulations and uses thereof | |
| RU2006103280A (ru) | Производные инсулина | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| ATE10364T1 (de) | Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p. | |
| GB1395090A (en) | Stabilized hormone compositions | |
| KR890003409A (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
| ES2168295T3 (es) | Factor estimulante oseo. | |
| KR20220044947A (ko) | 진균 감염의 치료를 위한 조성물 및 방법(compositions and methods for treatment of fungal infections) | |
| GB1046523A (en) | New preparations with adrenocorticotropic hormone activity and the manufacture thereof | |
| GB1309150A (en) | Acthactive peptides and process for their manufacture | |
| HUP9602024A2 (hu) | Aminosavtartalmú, külsőlegesen használható, gyógyhatású készítmény | |
| Dua et al. | Effects of parathyroid hormone and parathyroid hormone‐related protein on the rates of absorption of magnesium, calcium, sodium, potassium and phosphate ions from the reticulo‐rumen of sheep | |
| JP2019520336A5 (pm) | ||
| RU95113498A (ru) | Линейные или циклические олигопептиды, обладающие сродством к опиоидным рецепторам, фармацевтическая композиция, способ лечения | |
| IE38514L (en) | Insulin preparations. |